Anixa Biosciences
Update in progressANIX (NasdaqCM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Anixa Biosciences, Inc. is a San Jose, California–based biotechnology company focused on oncology therapeutics and cancer vaccines. Its programs include liraltagene autoleucel, a CAR-T–style therapy aimed at ovarian cancer, and efforts to develop a breast cancer vaccine, along with a vaccine discovery program to create vaccines for hard-to-treat cancers such as lung, colon, and prostate cancers. Formerly ITUS Corporation, it was renamed in 2018; founded in 1982.
Company score
- Sentiment
- 0.29
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.19
- Governance
- 0.10
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.08
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.18
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqCM (NCM)
- LocationUnited States
- CEODr. Amit Kumar Ph.D.
- Founded1982
- Employees4
- Websitewww.anixa.com
Identifiers
- ISINUS03528H1095
- FIGIBBG000BG3J79
- LEI549300PW2C2QTAJL2D19
- CUSIP03528H109
- CIK0000715446